Evercore ISI Group Maintains Outperform on Travere Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko has maintained an 'Outperform' rating on Travere Therapeutics (NASDAQ:TVTX), but lowered the price target from $30 to $14.
September 22, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Evercore ISI Group has maintained an 'Outperform' rating on Travere Therapeutics, but lowered the price target from $30 to $14.
The lowering of the price target by Evercore ISI Group from $30 to $14 indicates a potential decrease in the short-term value of Travere Therapeutics' stock. However, the 'Outperform' rating suggests that the stock is still expected to do better than the market average.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100